Crunch time for funding of universal access to antiretroviral treatment for people with HIV infection

International Journal of Clinical Practice

Volumn 65, Issue 8, 2011, Pages 824-827

  Maher, D ^a,b   Von Schoen Angerer, T ^c   Cohn, J ^c,d  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c MÉDECINS SANS FRONTIÈRES   (Switzerland)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; TENOFOVIR;

AFRICA; CONSENSUS; DEVELOPING COUNTRY; DIAGNOSTIC TEST; FUNDING; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; TREATMENT RESPONSE; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; DEVELOPING COUNTRIES; FINANCING, ORGANIZED; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS;

EID: 79960478930     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02697.x     Document Type: Review

References (33)

1. UNAIDS. AIDS epidemic update 2009. (accessed 21 January 2011)
2. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A,. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2: e298.
3. Bailey RC, Moses S, Parker CB, et al., Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369: 643-56. (Pubitemid 46281312)
4. Gray RH, Kigozi G, Serwadda D, et al., Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369: 657-66.
5. Padian NS, McCoy SI, Balkus JE, Wasserheit JN,. Weighing the gold in the gold standard: challenges in HIV prevention research. AIDS 2010; 24: 621-35.
6. Karim QA, Karim SS, Frohlich JA, et al., for the CAPRISA 004 trial group. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-74.
7. Phillips AN, Sabin CA, Pillay D, Lundgren JD,. HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. HIV Medicine 2007; 8: 536-46. (Pubitemid 47616833)
8. Jahn A, Floyd S, Crampin AC, et al., Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008; 371: 1603-11. (Pubitemid 351626844)
9. World Health Organization, UNAIDS, UNICEF. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2010. Geneva: World Health Organization, 2009. (accessed 14 November 2010)
10. Maher D,. Implications of the global financial crisis for the response to diseases of poverty within overall health sector development: the case of tuberculosis. Trop Med Int Health 2010; 15 (1): 11-17.
11. Kates J, Boortz K, Lief E, Avila C, Gobet B,. Financing the Response to AIDS in Low- and Middle-Income Countries: International Assistance from the G8, European Commission and Other Donor Governments in 2009. Washington, DC: Kaiser Family Foundation, 2010. (accessed 14 November 2010)
12. UNAIDS. The global economic crisis and HIV prevention and treatment programmes: vulnerabilities and impact. UNAIDS report 2009. (accessed 14 November 2010)
13. Global Fund Third Voluntary Replenishment 2011-2013. Pledges for 2011-2013 at 5 October 2010.
14. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach. 2010. (accessed 18 November 2010)
15. Roehr B,. More people face treatment rationing as AIDS funding is cut. British Medical Journal 2010; 340: c2284.
16. Von Schoen-Angerer T,. Putting patients above politics (Letter). Lancet 2010; 376: 1301-2.
17. Atun RA, Gurol-Urganci I, McKee M, Health systems and older people with HIV and AIDS. Lessons can be learnt from the extensive experience in other chronic disorders (Editorial). Br Med J 2009; 339: 308-9.
18. Attia S, Egger M, Müller M, Zwahlen M, Low N,. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23: 1397-404.
19. Padian NS, Buvé A, Balkus J, Serwadda D, Cates W,. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 2008; 372: 585-99.
20. Donnell D, Baeten JM, Kiarie J, et al., Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375: 2092-08.
21. Garnett GP, Baggaley RF,. Treating our way out of the HIV pandemic: could we, would we, should we? Lancet 2008; 373: 9-11.
22. Maher D, Harries AD,. Quality care: a link between clinical and public health approaches to HIV infection in developing countries. Trop Med Int Health 2010; 15 (4): 391-5.
23. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG,. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2008; 373: 48-57.
24. De Cock KM, Gilks CF, Lo Y-R, Guerma T,. Can antiretroviral therapy eliminate HIV transmission? Lancet 2008; 371: 752-9.
25. Bautista-Arredondo S, Wirtz VJ, Bertozzi S,. Improving access to treatment for HIV in sub-Saharan Africa. Br Med J 2010; 341: 1173-4.
26. Feachem R, Yarmey G, Schrade C,. A moment of truth for global health. (Editorial). Br Med J 2010; 340: 1316-7.
27. Maher D,. Re-thinking global health sector efforts for HIV and tuberculosis epidemic control: promoting integration of programme activities within a strengthened health system. BMC Public Health 2010; 10: 394.
28. Jaffar S, Amuron B, Foster S, et al., on behalf of the Jinja trial team. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised trial. Lancet 2009; 374: 2080-9.
29. DART trial team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomized non-inferiority trial. Lancet 2010; 375: 123-31.
30. Koole O, Colebunders R,. ART in low-resource settings: how to do more with less. (Comment). Lancet 2010; 376: 396-8.
31. Médecins Sans Frontières. Untangling the Web of Antiretroviral Price Reductions, 13th edn. Geneva: Medecins sans Frontieres. 2010.
32. Moszynski P,. India-EU free trade agreement threatens access to generic drugs, MSF warns. Br Med J 2010; 340: c2309.
33. Graves R,. The Greek Myths, Volume 1, Revised edn. London: Penguin, 1960.